Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases (2018)
Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases.
- 1
- North Wales Department of Psychological Medicine, Bangor, Wales, UK.
- 2
- David Braley and Nancy Gordon Chair of Family Medicine, Department of Family Medicine, McMaster University, ON, Canada.
Abstract
OBJECTIVE:
To investigate clinical reports of post-SSRI sexual dysfunction (PSSD), post-finasteride syndrome (PFS) and enduring sexual dysfunction following isotretinoin.
METHODS:
Data from RxISK.org, a global adverse event reporting website, have been used to establish the clinical features, demographic details and clinical trajectories of syndromes of persistent sexual difficulties following three superficially different treatment modalities.
RESULTS: We report on 300 cases of enduring sexual dysfunction from 37 countries following 14 different drugs comprised of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors and isotretinoin. While reports of certain issues were unique to the antidepressants, such as the onset of premature ejaculation and persistent genital arousal disorder (PGAD), there was also a significant overlap in symptom profile between the drug groups, with common features including genital anaesthesia, pleasureless or weak orgasm, loss of libido and impotence. Secondary consequences included relationship breakdown and impaired quality of life.
CONCLUSIONS: These data point to a legacy syndrome or syndromes comprising a range of disturbances to sexual function. More detailed studies will require developments in coding systems that recognise the condition(s). Further exploration of these tardive sexual syndromes may yield greater understanding of tardive syndromes in general.
RESULTS: We report on 300 cases of enduring sexual dysfunction from 37 countries following 14 different drugs comprised of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors and isotretinoin. While reports of certain issues were unique to the antidepressants, such as the onset of premature ejaculation and persistent genital arousal disorder (PGAD), there was also a significant overlap in symptom profile between the drug groups, with common features including genital anaesthesia, pleasureless or weak orgasm, loss of libido and impotence. Secondary consequences included relationship breakdown and impaired quality of life.
CONCLUSIONS: These data point to a legacy syndrome or syndromes comprising a range of disturbances to sexual function. More detailed studies will require developments in coding systems that recognise the condition(s). Further exploration of these tardive sexual syndromes may yield greater understanding of tardive syndromes in general.
KEYWORDS:
Post-SSRI sexual dysfunction (PSSD); antidepressants; erectile dysfunction; finasteride; isotretinoin; selective serotonin reuptake inhibitors (SSRIs)
- PMID:
- 29733030
- DOI:
- 10.3233/JRS-180744
TRADUZIONE ITALIANA:
Abstract
OBBIETTIVO:
Per indagare i rapporti clinici di disfunzione sessuale post-SSRI (PSSD), sindrome post-finasteride (PFS) e disfunzione sessuale persistente post-isotretinoina.
METODI:
I dati di RxISK.org, un sito Web globale di segnalazione degli eventi avversi, sono stati utilizzati per stabilire le caratteristiche cliniche, i dettagli demografici e le traiettorie cliniche delle sindromi di difficoltà sessuali persistenti in seguito a tre modalità di trattamento superficialmente differenti.
RISULTATI
Riportiamo 300 casi di disfunzione sessuale duratura da 37 paesi in seguito a 14 diversi farmaci comprendenti gli antidepressivi inibitori della ricaptazione della serotonina, gli inibitori della 5α-riduttasi e l'isotretinoina. Mentre le segnalazioni di alcuni problemi erano esclusiva degli antidepressivi, come l'insorgenza di eiaculazione precoce e disturbo dell'eccitazione genitale persistente (PGAD), c'era anche una significativa sovrapposizione nel profilo dei sintomi tra i gruppi di farmaci, con caratteristiche comuni tra cui l'anestesia genitale, orgasmo debole o senza piacere, perdita di libido e impotenza. Le conseguenze secondarie includevano la disgregazione della relazione e la qualità della vita compromessa.
CONCLUSIONI
Questi dati indicano una sindrome o sindromi insorte con l'utilizzo di farmaci che comprendono una serie di disturbi alla funzione sessuale. Studi più dettagliati richiederanno sviluppi nei sistemi di codifica che riconoscono le condizioni. Un'ulteriore esplorazione di queste sindromi sessuali tardive può portare a una maggiore comprensione delle sindromi tardive in generale.
CLICCA QUI PER LEGGERE IL TESTO COMPLETO TRADOTTO IN ITALIANO